Metabolic reprogramming drives acquired venetoclax resistance in Acute Myeloid Leukemia and reveals targetable vulnerabilities (2025)
- Authors:
- USP affiliated authors: CÂMARA, NIELS OLSEN SARAIVA - ICB ; LOTUFO, LETICIA VERAS COSTA - ICB ; REGO, EDUARDO MAGALHÃES - FM ; MACHADO NETO, JOÃO AGOSTINHO - ICB ; LIMA, KELI CRISTINA DE - FM ; QUEIROZ, GUSTAVO NERY DE - ICB ; CIPELLI, MARCELLA - ICB
- Unidades: ICB; FM
- DOI: 10.1182/blood-2025-6785
- Subjects: FARMCACOLOGIA; IMUNOLOGIA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Washington
- Date published: 2025
- Source:
- Conference titles: ASH Annual Meeting and Exposition
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
LIMA, Keli Cristina de et al. Metabolic reprogramming drives acquired venetoclax resistance in Acute Myeloid Leukemia and reveals targetable vulnerabilities. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2025-6785. Acesso em: 25 fev. 2026. , 2025 -
APA
Lima, K. C. de, Queiroz, G. N. de, Cipelli, M., Tomaz, V., Cortes, L. G. F., Silva, M. B., et al. (2025). Metabolic reprogramming drives acquired venetoclax resistance in Acute Myeloid Leukemia and reveals targetable vulnerabilities. Blood. Washington: Instituto de Ciências Biomédicas, Universidade de São Paulo. doi:10.1182/blood-2025-6785 -
NLM
Lima KC de, Queiroz GN de, Cipelli M, Tomaz V, Cortes LGF, Silva MB, Guedes R, Campregher PV, Câmara NOS, Costa-Lotufo LV, Rego EM, Machado Neto JA. Metabolic reprogramming drives acquired venetoclax resistance in Acute Myeloid Leukemia and reveals targetable vulnerabilities [Internet]. Blood. 2025 ; 146 6785.[citado 2026 fev. 25 ] Available from: https://doi.org/10.1182/blood-2025-6785 -
Vancouver
Lima KC de, Queiroz GN de, Cipelli M, Tomaz V, Cortes LGF, Silva MB, Guedes R, Campregher PV, Câmara NOS, Costa-Lotufo LV, Rego EM, Machado Neto JA. Metabolic reprogramming drives acquired venetoclax resistance in Acute Myeloid Leukemia and reveals targetable vulnerabilities [Internet]. Blood. 2025 ; 146 6785.[citado 2026 fev. 25 ] Available from: https://doi.org/10.1182/blood-2025-6785 - Metabolic reprogramming represents a targetable mechanism to overcome acquired resistance to venetoclax in acute myeloid leukemia
- NT157 exhibits antineoplastic effects by targeting IRS and STAT3/5 signaling in multiple myeloma
- Gut microbiota resilience mechanisms against pthogen infection and its role in infammatory Bowel Disease
- Cellular and molecular effects of Eribulin in preclinical models of hematologic neoplasms
- In Silico, in vitro, and in vivo studies of a 2-substituted quinazolin-4(3H)-one in T-cell acute lymphoblastic leukemia
- Synthesis and evaluation of 2-substituted quinazolin-4(3H)-ones as potential antileukemic agents
- All-trans retinoic acid potentiates cell death induced by quizartinib in acute myeloid leukemia with FLT3-ITD mutations
- Translational investigation of tolinapant (ASTX660) in acute myeloid leukemia by integrating clinical, bioinformatic and pharmacological approaches
- Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia
- The survivin/XIAP suppressant YM155 impairs clonal growth and induces apoptosis in JAK2V617F cells
Informações sobre o DOI: 10.1182/blood-2025-6785 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
